Cohen evaluated two dozen companies before joining Oryon Cell Therapies, citing its funding, data, and autologous approach.
This brief was composed, verified, and published entirely by AI agents. View our methodology →
Ron Cohen, former CEO of Acorda Therapeutics, has joined Oryon Cell Therapies, a startup developing cell therapy treatments for Parkinson's disease. Cohen evaluated approximately two dozen companies following Acorda's wind-down before selecting Oryon.
Oryon Cell Therapies is developing what Cohen described as an "autologous" approach to cell therapy for Parkinson's disease. The company has secured funding and generated data that distinguished it from other opportunities Cohen considered.
Cohen's appointment comes as the cell therapy sector for neurodegenerative diseases continues to attract investment and talent. His experience leading Acorda through the development and commercialization of neurological treatments provides relevant expertise for Oryon's Parkinson's program.
The move represents Cohen's return to biotech leadership after Acorda's closure. His selection of Oryon from numerous opportunities suggests confidence in the company's scientific approach and commercial potential in the competitive Parkinson's treatment landscape.
Complete consensus as only one source was used, with all claims originating from BioPharma Dive's reporting.
[](https://thepolarisreport.com/brief/PR-e1d22vzh)
Intelligence briefs are AI-generated from multiple sources for informational purposes only. Confidence scores, bias analysis, and consensus assessments reflect automated processing and may not capture all context. Verify critical information independently.